Epizyme Inc (Epizyme) is a biopharmaceutical company that discovers, develops, and markets novel epigenetic therapies for the treatment of cancer and other diseases. The company’s marketed products include Tazverik (tazemetostat), an oral, first-in-class, small-molecule inhibitor of EZH2 for the treatment of patients with metastatic or locally advanced epithelioid sarcoma and relapsed/refractory follicular lymphoma. Its pipeline products include tazemetostat for follicular lymphoma, DLBCL, epithelioid sarcoma and prostate cancer; PRMT 1 Inhibitor (GSK3368715) for solid tumors and DLBCL; and PRMT5 (GSK3368715) for solid tumors and blood cancer. The company develops products through a proprietary drug discovery platform and collaboration with other companies. Epizyme is headquartered in Cambridge, Massachusetts, the US.

Headquarters United States of America

Address 400 Technology Sq Ste 4, Cambridge, Massachusetts, 02139-3584


Telephone 1 617 2295872

No of Employees 250

Industry Pharmaceuticals and Healthcare

Revenue (2021) $37.4M

   

   

Access premium data and analytics for Epizyme Inc

80+

Catalyst Calendar

Proactively evaluate Epizyme Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

70+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Epizyme Inc’s relevant decision makers and contact details.

40+

Clinical Trials

Determine Epizyme Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

20+

Pipeline Drugs

Identify which of Epizyme Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

8

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

3

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Marketed Drugs

Understand Epizyme Inc’s commercialized product portfolio to stay one step ahead of the market.

40+

Install Base

Install Base provides a holistic and a granular view of the IT product/service deployments from leading vendors. Explore IT infrastructure categories, solution and product/service areas deployed by a prospect.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Epizyme Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Brands
Marketed Tazverik
Tazverik: Epizyme
Epithelioid Sarcoma
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Contracts/Agreements In June, the company entered into an agreement to be acquired by Ipsen.
2021 Regulatory Approval In November, the company was granted Fast Track designation for the Company’s novel, first-in-class, oral SETD2 inhibitor for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
2021 New Products/Services In November, the company launched In My Blood that is an online resource designed to empower people living with follicular lymphoma.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Epizyme Inc Johnson & Johnson Pfizer Inc Novartis AG Merck & Co Inc
Headquarters United States of America United States of America United States of America Switzerland United States of America
City Cambridge New Brunswick New York Basel Kenilworth
State/Province Massachusetts New Jersey New York - New Jersey
No. of Employees 250 141,700 79,000 108,000 68,000
Entity Type Private Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Executives
Name Position Board Since Age
David M. Mott Chairman Executive Board 2016 56
Grant Bogle Director; President; Chief Executive Officer Executive Board 2021 64
Jerald Korn Chief Operating Officer Senior Management 2022 -
Jeffery L. Kutok, M.D., Ph.D. Chief Scientific Officer Senior Management 2020 55
Tanja Weber Chief Business Officer Senior Management - -
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company Analytics

Contact the team or request a demo to find out how our data can drive your business forward

Why are you leaving?